A new duet in cancer biology: AMPK the typical and UBE2O the atypical

Isabelle K. Vila; Su Jung Song; Min Sup Song

doi:10.1080/23723556.2017.1304846

A new duet in cancer biology: AMPK the typical and UBE2O the atypical

Isabelle K. Vila, Su Jung Song, Min Sup Song

Molecular & Cellular Oncology

Research output: Contribution to journal › Article › peer-review

6 Scopus citations

Abstract

Ubiquitin-conjugating enzyme E2O (UBE2O) is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of UBE2O reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1–hypoxia-inducible factor 1-α pathway. Critically, UBE2O targets adenosine monophosphate (AMP)-activated protein kinase-α 2 (AMPKα2) for ubiquitination and degradation. We thus suggest the UBE2O-AMPKα2 axis as a potential therapeutic target for cancer.

Original language	English (US)
Article number	e1304846
Journal	Molecular and Cellular Oncology
Volume	4
Issue number	3
DOIs	https://doi.org/10.1080/23723556.2017.1304846
State	Published - May 4 2017

Keywords

AMPK
AMPKα2
HIF1α
UBE2O
arsenite
breast cancer
cancer metabolism
mTOR
prostate cancer
ubiquitination

ASJC Scopus subject areas

Molecular Medicine
Cancer Research

Access to Document

10.1080/23723556.2017.1304846

Cite this

@article{3c64e741f40842f38f108a2f40d44c73,

title = "A new duet in cancer biology: AMPK the typical and UBE2O the atypical",

abstract = "Ubiquitin-conjugating enzyme E2O (UBE2O) is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of UBE2O reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1–hypoxia-inducible factor 1-α pathway. Critically, UBE2O targets adenosine monophosphate (AMP)-activated protein kinase-α 2 (AMPKα2) for ubiquitination and degradation. We thus suggest the UBE2O-AMPKα2 axis as a potential therapeutic target for cancer.",

keywords = "AMPK, AMPKα2, HIF1α, UBE2O, arsenite, breast cancer, cancer metabolism, mTOR, prostate cancer, ubiquitination",

author = "Vila, {Isabelle K.} and Song, {Su Jung} and Song, {Min Sup}",

note = "Funding Information: This work was supported by a grant of the Soonchunhyang University Research Fund and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI15C2679) to S.J.S., and a Cancer Prevention Research Institute of Texas grant (RP150084), a Department of Defense grant (W81XWH-15–1–0662), and a NIH grant (CA196740) to M.S.S. Publisher Copyright: {\textcopyright} 2017, {\textcopyright} 2017 Taylor & Francis Group, LLC.",

year = "2017",

month = may,

day = "4",

doi = "10.1080/23723556.2017.1304846",

language = "English (US)",

volume = "4",

journal = "Molecular and Cellular Oncology",

issn = "2372-3556",

publisher = "Taylor and Francis Ltd.",

number = "3",

}

TY - JOUR

T1 - A new duet in cancer biology

T2 - AMPK the typical and UBE2O the atypical

AU - Vila, Isabelle K.

AU - Song, Su Jung

AU - Song, Min Sup

N1 - Funding Information: This work was supported by a grant of the Soonchunhyang University Research Fund and a grant of the Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI) funded by the Ministry of Health & Welfare, Republic of Korea (Grant number: HI15C2679) to S.J.S., and a Cancer Prevention Research Institute of Texas grant (RP150084), a Department of Defense grant (W81XWH-15–1–0662), and a NIH grant (CA196740) to M.S.S. Publisher Copyright: © 2017, © 2017 Taylor & Francis Group, LLC.

PY - 2017/5/4

Y1 - 2017/5/4

N2 - Ubiquitin-conjugating enzyme E2O (UBE2O) is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of UBE2O reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1–hypoxia-inducible factor 1-α pathway. Critically, UBE2O targets adenosine monophosphate (AMP)-activated protein kinase-α 2 (AMPKα2) for ubiquitination and degradation. We thus suggest the UBE2O-AMPKα2 axis as a potential therapeutic target for cancer.

AB - Ubiquitin-conjugating enzyme E2O (UBE2O) is upregulated in human cancers. We have demonstrated that genetic deletion or pharmacological blockade of UBE2O reduces tumorigenesis through inhibiting the mammalian target of rapamycin complex 1–hypoxia-inducible factor 1-α pathway. Critically, UBE2O targets adenosine monophosphate (AMP)-activated protein kinase-α 2 (AMPKα2) for ubiquitination and degradation. We thus suggest the UBE2O-AMPKα2 axis as a potential therapeutic target for cancer.

KW - AMPK

KW - AMPKα2

KW - HIF1α

KW - UBE2O

KW - arsenite

KW - breast cancer

KW - cancer metabolism

KW - mTOR

KW - prostate cancer

KW - ubiquitination

UR - http://www.scopus.com/inward/record.url?scp=85050392070&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85050392070&partnerID=8YFLogxK

U2 - 10.1080/23723556.2017.1304846

DO - 10.1080/23723556.2017.1304846

M3 - Article

C2 - 28616582

AN - SCOPUS:85050392070

SN - 2372-3556

VL - 4

JO - Molecular and Cellular Oncology

JF - Molecular and Cellular Oncology

IS - 3

M1 - e1304846

ER -

A new duet in cancer biology: AMPK the typical and UBE2O the atypical

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this